Grifols (NASDAQ:GRFS) Stock Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $8.72 and traded as high as $9.90. Grifols shares last traded at $9.86, with a volume of 338,734 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on GRFS shares. Wall Street Zen raised shares of Grifols from a “buy” rating to a “strong-buy” rating in a report on Monday, July 7th. JPMorgan Chase & Co. upped their price objective on shares of Grifols from $7.60 to $10.30 and gave the stock a “neutral” rating in a research note on Tuesday, June 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Grifols in a research note on Tuesday, August 5th. Finally, Zacks Research upgraded Grifols to a “hold” rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Grifols currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.30.

Grifols Stock Performance

The firm has a fifty day moving average of $10.13 and a 200-day moving average of $8.72. The firm has a market cap of $6.78 billion, a P/E ratio of 8.43, a PEG ratio of 0.34 and a beta of 0.64. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20.

Grifols Announces Dividend

The firm also recently disclosed a special dividend, which was paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th were paid a $0.1404 dividend. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols’s dividend payout ratio (DPR) is presently 11.97%.

Institutional Trading of Grifols

Institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc acquired a new stake in Grifols during the 1st quarter worth $28,000. EverSource Wealth Advisors LLC grew its stake in shares of Grifols by 127.4% during the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 4,604 shares during the period. Ameriprise Financial Inc. acquired a new stake in shares of Grifols during the second quarter worth $95,000. R Squared Ltd acquired a new stake in shares of Grifols during the second quarter worth $95,000. Finally, Ballentine Partners LLC bought a new position in Grifols during the first quarter worth about $77,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.